Proposed monographs for omission from the BP 2024
The British Pharmacopoeia is continuing to ensure that the publication remains relevant and comprehensive. As part of this work, several monographs included in the current edition of the British Pharmacopoeia have been proposed for omission due to the lack of UK based Marketing Authorisation Holders and/or low usage within the UK.
The monographs proposed for omission from the BP 2024 are:
Medicinal Substances
- Diflucortolone Valerate
- Estramustine Sodium Phosphate
- Melatonin*
- Papaveretum
Formulated Preparations
- Aspirin Effervescent Tablets
- Colistin Tablets
- Diethylstilbestrol Tablets
- Diflucortolone Cream
- Diflucortolone Oily Cream
- Diflucortolone Ointment
- Ephedrine Elixir
- Estramustine Phosphate Capsules
- Salbutamol Prolonged-release Capsules
- Somatropin Injection*
*These BP monographs have been superseded by the corresponding Ph Eur monographs.
The British Pharmacopoeia is used in many countries and we welcome feedback from national and international stakeholders regarding the proposed omissions. Monographs omitted f rom the BP 2024 publications will remain available within the BP Archive, which is accessible via the BP Online publication. Such monographs continue to remain in force under the Human Medicines Regulations 2012.
Please send any comments or objections to fiona.swanson@mhra.gov.uk .
The deadline for response is 1st March 2023.